Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Conditions
Brief summary
This phase I trial tests the safety, side effects, best dose and how well giving IL-18 armored STEAP1 CAR T cells after lymphodepleting chemotherapy (with cyclophosphamide and fludarabine) works for the treatment of castration resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Giving chemotherapy, with cyclophosphamide and fludarabine, prior to CAR T cells helps kill cancer cells in the body and prepare the body to receive the CAR T cells. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving IL-18 armored STEAP1 CAR T cells after lymphodepleting chemotherapy may be safe, tolerable and/or effective in treating patients with metastatic castration resistant prostate cancer.
Detailed description
OUTLINE: Patients undergo leukapheresis. Patients receive cyclophosphamide intravenously (IV) and fludarabine IV on days -5 to -3. Patients receive FH-STEAP1 IL-18 CAR T cell IV on day 0. Patients may continue to receive androgen deprivation therapy per standard of care, throughout the study. Patients undergo nuclear medicine bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan, tumor biopsy and blood sample collection throughout the study. Patients may also undergo multigated acquisition (MUGA) scan or echocardiography during screening. After completion of study treatment, patients are followed up on day +1, +3, +7, +10, +14, +21, + 28, months 2-6, month 9, month 12, then every 6 months until year 5 then yearly until year 15.
Interventions
BIOLOGICALFH-STEAP1 IL-18 CAR T cells
Given FH-STEAP1 IL-18 CAR T cells IV
DRUGAntiandrogen Therapy
Receive standard of care androgen deprivation therapy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREBone Scan
Undergo nuclear medicine bone scan
PROCEDUREComputed Tomography
Undergo CT scan
DRUGCyclophosphamide
Given IV
PROCEDUREEchocardiography Test
Undergo echocardiography
DRUGFludarabine
Given IV
PROCEDURELeukapheresis
Undergo leukapheresis
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
PROCEDUREMultigated Acquisition Scan
Undergo MUGA scan
PROCEDUREPositron Emission Tomography
Undergo PET scan
PROCEDUREBiopsy Procedure
Undergo tumor biopsy
Sponsors
Fred Hutchinson Cancer Center
PromiCell Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Documented, histologically confirmed adenocarcinoma of the prostate * Measurable disease by RECIST 1.1 criteria or bone only metastases with measurable PSA (≥ 1ng/mL) * Must have mCRPC with progressive disease (PD), stable disease (SD), lack of clinical benefit or intolerance to ≥ 1 line of systemic therapy, after becoming castration resistant * Have received the following for metastatic prostate cancer: * At least two lines of Food and Drug Administration (FDA)-approved therapies with at least one being a second-generation androgen receptor signaling inhibitor. * Targeted therapies for which they are eligible in the metastatic setting unless the patient has contraindications to receiving those medications, the agents are not available to the patient or the patient declines to receive these drugs due to personal preference * Castrate levels of testosterone (\< 50 ng/dL) with or without the use of androgen deprivation therapy * 18 years or older at the time of enrollment * Capable of understanding and providing written informed consent * Fertile male participants and their female partners must be willing to use an effective contraceptive method before, during, and for at least 4 months after the FH-STEAP1 IL-18 CAR T cell infusion * Participants will be permitted to receive radiation therapy for palliative purposes throughout the study period, except during the 2-week period prior to undergoing leukapheresis * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \> 50 mL/min as calculated using the Cockcroft-Gault formula and not dialysis dependent * Total bilirubin ≤ 1.5 x ULN. Participants with suspected Gilbert syndrome may be included if total bilirubin (bili) \> 3 mg/dL but no other evidence of hepatic dysfunction * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x ULN * ≤ grade 1 dyspnea and oxygen saturation (SaO2) ≥ 92% on ambient air. If pulmonary function tests (PFTs) are performed based on the clinical judgement of the treating physician, participants with forced expiratory volume at 1 second (FEVI) ≥ 50% of predicted and carbon monoxide diffusing capability (DLCO) (adjusted for lung volume) of ≥ 40% of predicted will be eligible * All participants ≥ 60 years of age are required to have left ventricular ejection fraction (LVEF) evaluation performed within 1 year prior to lymphodepletion chemotherapy. LVEF may be established with an echocardiogram or MUGA scan, and left ejection fraction must be ≥ 45% * Absolute neutrophil count (ANC) \> 1500 cells/ mm\^3 * Hemoglobin ≥ 9g g/dL * Platelets \> 100,000 per mm\^3
Exclusion criteria
* Expecting to conceive or father children for the duration of the trial through 4 months after T cell infusion * Patients that require immediate therapy due to mass effect or spinal cord compression * Active autoimmune disease: Participants with active autoimmune disease requiring chronic immunosuppressive therapy are excluded. Case by case exemptions are possible with approval by principal investigator (PI) * Corticosteroid therapy at a dose equivalent of \> 10 mg of prednisone per day (or equivalent). Pulsed corticosteroid use for disease control is acceptable * Concurrent use of other investigational anti-cancer agents except for androgen deprivation therapy * Uncontrolled concurrent illness: Participants may not have uncontrolled respiratory, endocrine, renal, gastrointestinal, genitourinary or systemic infection. There are exceptions to this criterion: * HIV positive participants on highly active antiretroviral therapy (HAART) with a CD4 count \> 500 cells/mm\^3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have hepatitis well controlled on medication; * Patients who have recent history of cerebrovascular accident, transient ischemic attack should be cleared by the neurology service before enrolling this study * Patients who have recent history of coronary artery disease or cardiac arrhythmia should be cleared by the cardiology service before enrolling this study. Case by case exemptions are possible with approval by PI * Participants with brain metastasis * Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune-related adverse events are excluded, with exception of hormone supplementation or corticosteroid therapy at equivalent of \> 10 mg prednisone (or equivalent) per day, unless otherwise approved by PI * Patients with a second malignancy in addition to their prostate cancer are not eligible if the second malignancy has required systemic treatment within the past 4 years or is not in complete remission. There are exceptions to this criterion: successfully treated non-metastatic basal cell and squamous cell skin carcinoma * Other medical, social, or psychiatric factor that interferes with medical appropriateness and/or ability to comply with study, as determined by the PI * Known allergic reactions to any of the components of study treatments * Participants who do not have a reasonable standard-of-care bridging therapy option available, as determined by the treating medical oncologist, to maintain disease control should clinically significant disease progression or worsening symptoms occur during the screening and T-cell manufacturing period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment-related unexpected grade 3 or higher toxicity | Up to 28 days post infusion | — |
| Incidence of adverse events | Up to 28 days post infusion | — |
| Prostate cancer response | Up to 1 year post infusion | Assessed by Prostate Cancer Working Group 3 (PCWG3) criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | From initiation of protocol treatment to disease progression or death of any cause, up to 1 year post infusion | Will be analyzed using Kaplan-Meier method and the results will be summarized by the median with a 95% confidence interval if appropriate. |
| Overall survival | From initiation of protocol treatment to death of any cause, up to 1 year post infusion | Will be analyzed using Kaplan-Meier method and the results will be summarized by the median with a 95% confidence interval if appropriate. |
| Objective response rate | Up to 1 year post infusion | Defined as complete response or partial response by Response Evaluation Criteria in Solid Tumors 1.1 criteria and PCWG 3. |
| Stable disease | Up to 1 year post infusion | Assessed by RECIST 1.1 criteria and PCWG3. |
| Clinical benefit | Up to 1 year post infusion | Defined as overall response and stable disease assessed by RECIST 1.1 criteria and PCWG3. |
| Overall response | Up to 1 year post infusion | Assessed by immune RECIST criteria. |
| Prostate specific antigen (PSA) response | From baseline, up to 15 years | Defined as ≥ 50% reductions in PSA. The estimation with an exact 95% confidence interval will be provided. |
Countries
United States
Contacts
CONTACTFred Hutch Intake
PRINCIPAL_INVESTIGATORRosa Nadal Rios, MD, PhD
Fred Hutch/University of Washington Cancer Consortium
Outcome results
None listed